Authors
Latest:
Next Steps to Further Understand Uterine SarcomaMatthew A. Ingham, MD, discusses the key takeaways from an article he co-authored regarding novel therapeutics in uterine sarcoma.
Latest:
Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating AgentsExperts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.
Latest:
Trial Results Show Patients With RET Alterations Experience Different Efficacy With Lung Cancer TherapiesDuring a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.
Latest:
Keeping Track of FGFR Inhibitor AEs Leads to Optimal OutcomesThis article explorex some of the more frequently encountered toxicities of FGFR inhibitors and their optimal management.
Latest:
Phase 2 Trial of Selinexor Shows Durable Responses in DLBCLMichael Schuster, MD, discusses the efficacy of treatment with selinexor in patients with diffuse large B-cell lymphoma in the SADAL study.
Latest:
Caring for Patients With Cancer as COVID Rates Continue to RiseStringent and dedicated interventions are necessary to handle the spread of COVID-19, as this represents a major healthcare challenge for humanity, says Daniel Vorobiof, MD.
Latest:
Discussing Treatment Options and Recent Trials in the Thyroid Cancer SpaceMelanie Goldfarb, MD, MSc, FACS, FACE, discusses the current treatment landscape for patients with thyroid cancer.
Latest:
Unmet Needs and Future Directions for Ovarian CancerThomas C. Krivak MD, John K. Chan, MD, and Cecelia H. Boardman, MD, share insight on recent updates to maintenance therapy, unmet needs, and the future treatment landscape for ovarian cancer.
Latest:
Pembrolizumab Improves PFS in Hodgkin Lymphoma Compared With Brentuximab VedotinJohn Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.
Latest:
Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast CancerEcaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
Latest:
SCLC: Treatment Advancing 1 Small, but Quickening, Step at a TimeIn 2019, there were approximately 30,000 new cases of small cell lung cancer diagnosed in the United States with nearly all cases attributable to cigarette smoking.
Latest:
Cervical Cancer Awareness Month: Dramatic Increase in Cervical Cancer Research Is Driving Treatment ProgressFor cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.
Latest:
Turning Inspiration Into Innovation: Hazim’s Impact on OncologyAntonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.
Latest:
World Lung Cancer Day: Multiple Barriers Result in Low Lung Cancer Screening RatesAlthough lung cancer screening rates are currently low, identifying the obstacles and potential solutions may raise the number of screenings in the United States.
Latest:
BPDCN: Future Directions in CareClosing out their discussion on the management of blastic plasmacytoid dendritic cell neoplasm, expert panelists look toward the future treatment paradigm.
Latest:
Omidubicel Increases Availability of Allogeneic Stem Cell TransplantChenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.
Latest:
Lisberg Discusses Dato-DXd's Role in Advanced Lung Cancer CareIn this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Advancing the Treatment of Alveolar Soft Part SarcomaIn season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.
Latest:
Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant MelanomaAxel Hauschild, MD, PhD, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib and trametinib compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.
Latest:
Discussing Daratumumab’s Ongoing Impact on Multiple Myeloma TreatmentJoseph Mikhael, MD, discusses the ongoing impact of daratumumab in the treatment landscape of patients with multiple myeloma.
Latest:
Discussing the Role of Tivozanib in the Third-Line of RCC TreatmentWith updated data for the usefulness of tivozanib, patients with recurrent clear cell renal carcinoma have an effective option for treatment in a treatment landscape previously without many treatment options.
